Journal of Clinical Oncology, Vol 8, 527-537, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

RJ Jones, S Piantadosi, RB Mann, RF Ambinder, EJ Seifter, HM Vriesendorp, MD Abeloff, WH Burns, WS May and SD Rowley
Johns Hopkins Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD 21205.

Patients with Hodgkin's disease who have failed two or more chemotherapy regimens or who have relapsed after an initial chemotherapy-induced remission of less than 12 months are seldom cured with conventional salvage therapies. We studied the effect of high-dose cytoreductive therapy followed by bone marrow transplantation in 50 such patients with relapsed Hodgkin's disease. Twenty-one patients with histocompatibility locus antigen (HLA)-matched donors had allogeneic marrow transplants, one patient received marrow from an identical twin, and 28 patients without a matched donor received autologous grafts purged with 4-hydroperoxycyclophosphamide. Busulfan plus cyclophosphamide was the preparative regimen for the 25 patients who had received extensive prior irradiation, and the other 25 patients received cyclophosphamide plus total body irradiation. The overall actuarial probability of event-free survival at 3 years was 30%, with a median follow-up of 26 months. The event-free survival following transplantation was influenced by the number of chemotherapy failures and the patient's response to conventional salvage therapy prior to transplant. The 16 patients who were transplanted at first relapse, while still responsive to standard therapy, had a 64% actuarial probability of event-free survival at 3 years. Age, presence of extranodal disease, preparative regimen, and type of graft (autologous v allogeneic) were not significant prognostic factors. The majority of transplant-related deaths were from interstitial pneumonitis; inadequate pulmonary function, multiple prior chemotherapy regimens, and prior chest irradiation all appeared to increase the transplant- related mortality. These results suggest a role for marrow transplantation in a subset of patients with relapsed Hodgkin's disease who are unlikely to be otherwise cured but are still responsive to conventional-dose cytoreductive therapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540. [Abstract] [Full Text] [PDF]

				G. Akpek, R. F. Ambinder, S. Piantadosi, R. A. Abrams, R. A. Brodsky, G. B. Vogelsang, M. L. Zahurak, D. Fuller, C. B. Miller, S. J. Noga, et al. Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Lymphoma J. Clin. Oncol., December 1, 2001; 19(23): 4314 - 4321. [Abstract] [Full Text]

				A. M. Carella, M. Cavaliere, E. Lerma, R. Ferrara, L. Tedeschi, A. Romanelli, M. Vinci, G. Pinotti, P. Lambelet, C. Loni, et al. Autografting Followed by Nonmyeloablative Immunosuppressive Chemotherapy and Allogeneic Peripheral-Blood Hematopoietic Stem-Cell Transplantation as Treatment of Resistant Hodgkin's Disease and Non-Hodgkin's Lymphoma J. Clin. Oncol., December 1, 2000; 18(23): 3918 - 3924. [Abstract] [Full Text] [PDF]

				J. A. Bogart, C. Ungureanu, S. Ryu, C. T. Chung, and K. W. Zamkoff Hematologic Toxic Reaction to Radiation Therapy Adjuvant to Autologous Peripheral Blood Stem Cell Transplantation for Recurrent or Refractory Hodgkin Disease Radiology, February 1, 2000; 214(2): 421 - 425. [Abstract] [Full Text]

				A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Decision Analysis on Alternative Treatment Strategies for Favorable-Prognosis, Early-Stage Hodgkin's Disease J. Clin. Oncol., November 1, 1999; 17(11): 3577 - 3585. [Abstract] [Full Text] [PDF]

				C. Aristei and A. Tabilio Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases Oncologist, October 1, 1999; 4(5): 386 - 397. [Abstract] [Full Text]

				A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Laparotomy Versus No Laparotomy in the Management of Early-Stage, Favorable-Prognosis Hodgkin's Disease: A Decision Analysis J. Clin. Oncol., January 1, 1999; 17(1): 241 - 241. [Abstract] [Full Text] [PDF]

				G. I. Rodriguez, J. G. Kuhn, G. R. Weiss, S. G. Hilsenbeck, J. R. Eckardt, A. Thurman, D. A. Rinaldi, S. Hodges, D. D. Von Hoff, and E. K. Rowinsky A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea Blood, March 1, 1998; 91(5): 1533 - 1541. [Abstract] [Full Text] [PDF]

				A. P. Sing, R. F. Ambinder, D. J. Hong, M. Jensen, W. Batten, E. Petersdorf, and P. D. Greenberg Isolation of Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes That Lyse Reed-Sternberg Cells: Implications for Immune-Mediated Therapy of EBV+ Hodgkin's Disease Blood, March 15, 1997; 89(6): 1978 - 1986. [Abstract] [Full Text] [PDF]

				A. D. Hess, E. C. Bright, C. Thoburn, G. B. Vogelsang, R. J. Jones, and M. J. Kennedy Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide Blood, March 15, 1997; 89(6): 2203 - 2209. [Abstract] [Full Text] [PDF]

				S. J. Horning, N. J. Chao, R. S. Negrin, R. T. Hoppe, G. D. Long, W. W. Hu, R. M. Wong, B. W. Brown, and K. G. Blume High-Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis of the Stanford University Results and Prognostic Indices Blood, February 1, 1997; 89(3): 801 - 813. [Abstract] [Full Text] [PDF]

				A. R. Yuen, S. A. Rosenberg, R. T. Hoppe, J. D. Halpern, and S. J. Horning Comparison Between Conventional Salvage Therapy and High-Dose Therapy With Autografting for Recurrent or Refractory Hodgkin's Disease Blood, February 1, 1997; 89(3): 814 - 822. [Abstract] [Full Text] [PDF]

				J. O. Armitage Bone Marrow Transplantation N. Engl. J. Med., March 24, 1994; 330(12): 827 - 838. [Full Text]

				M. L. Grossbard and N. L. Harris Case 10-1994- A 37-Year-Old Woman with Thrombocytopenia and a Paragastric Mass after Treatment for Hodgkin's Disease N. Engl. J. Med., March 10, 1994; 330(10): 698 - 704. [Full Text]

				V. T. DeVita and S. M. Hubbard Hodgkin's Disease N. Engl. J. Med., February 25, 1993; 328(8): 560 - 565. [Full Text]

				S. C. Gulati and C. L. Bennett Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease Ann Intern Med, February 1, 1992; 116(3): 177 - 182. [Abstract] [PDF]